T1	Participants 703 883	previously untreated adult APL patients registered to protocol INT 0129 by the Eastern Cooperative Oncology Group, the Southwest Oncology Group, and the Cancer and Leukemia Group B
T2	Participants 885 1098	Of 279 clinically eligible cases, 230 were molecularly evaluable, and of these, 111 were randomized to receive remission induction therapy with all-trans retinoic acid (ATRA) and 119 with conventional chemotherapy
T3	Participants 1100 1179	Nine cases not excluded by central pathology review were PML-RAR alpha negative
T4	Participants 1280 1312	221 PML-RAR alpha-positive cases
